Published in J Pharmacol Exp Ther on October 02, 2006
Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol (2008) 1.70
Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11
Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair. Am J Sports Med (2014) 1.02
Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol (2008) 0.95
Rationally designed multitarget agents against inflammation and pain. Curr Med Chem (2013) 0.91
Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone. Br J Pharmacol (2011) 0.85
Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol (2008) 0.81
Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. Br J Pharmacol (2010) 0.78
The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. Eur J Clin Pharmacol (2017) 0.78
Potential Antifungal Targets against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review. Front Microbiol (2016) 0.76
Prediction of anti-inflammatory proteins/peptides: an insilico approach. J Transl Med (2017) 0.75
High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis (2007) 3.74
Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2007) 2.95
TGF-beta signaling in vascular fibrosis. Cardiovasc Res (2007) 2.86
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation (2005) 2.55
Biomarkers in cardiovascular medicine. Rev Esp Cardiol (2009) 2.34
Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res (2006) 1.81
NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant (2004) 1.78
Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int (2008) 1.77
Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant (2005) 1.76
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol (2003) 1.67
Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis (2008) 1.62
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 1.59
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.55
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2009) 1.52
Lead poisoning in United States-bound refugee children: Thailand-Burma border, 2009. Pediatrics (2012) 1.46
[Epidemiology of lipid profile of the Spanish elderly population: the EPICARDIAN study]. Med Clin (Barc) (2004) 1.44
The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol (2008) 1.43
AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol (2011) 1.40
Anti-inflammatory and immunomodulatory effects of statins. Kidney Int (2003) 1.39
Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl (2003) 1.39
The U.S.-Mexico Border Infectious Disease Surveillance project: establishing bi-national border surveillance. Emerg Infect Dis (2003) 1.38
Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation (2004) 1.33
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis (2002) 1.31
Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens (2006) 1.26
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.25
Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.25
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovasc Res (2010) 1.23
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.22
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant (2009) 1.21
Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation (2003) 1.21
Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep (2003) 1.20
Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 1.16
Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res (2008) 1.15
Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res (2005) 1.15
Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension (2009) 1.14
Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res (2005) 1.14
Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol (2011) 1.13
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke (2006) 1.12
Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis (2008) 1.11
Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol (2002) 1.09
Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One (2012) 1.09
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol (2013) 1.08
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis (2005) 1.08
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07
TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 1.07
Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med (2009) 1.07
3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes (2005) 1.07
Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate. Am J Kidney Dis (2002) 1.07
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol (2010) 1.05
HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension (2007) 1.03
Epithelioid hemangioendothelioma of the liver. J Hepatobiliary Pancreat Surg (2006) 1.02
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One (2010) 1.01
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis (2002) 1.01
CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol (2009) 1.01
Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res (2008) 1.01
Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl (2003) 1.01
Paracetamol-induced renal tubular injury: a role for ER stress. J Am Soc Nephrol (2004) 1.01
3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int (2005) 1.01
Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. Am J Clin Nutr (2004) 1.01
Short- and mid-term outcomes of sleeve gastrectomy for morbid obesity: the experience of the Spanish National Registry. Obes Surg (2009) 1.00
The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant (2010) 1.00
Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol (2003) 1.00
Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant (2010) 1.00
TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res (2010) 1.00
Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke (2003) 0.99
Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 0.99
Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 0.99
Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. Kidney Int Suppl (2003) 0.98
Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol (2004) 0.98
Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovasc Res (2009) 0.98
Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant (2008) 0.97
Beta-Cell hyperplasia induced by hepatic insulin resistance: role of a liver-pancreas endocrine axis through insulin receptor A isoform. Diabetes (2009) 0.96
Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int Suppl (2003) 0.96
Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-dependent respiratory burst: potential role in the perpetuation of immune nephritis. J Immunol (2003) 0.95
p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant (2013) 0.95
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke (2005) 0.95
NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke (2004) 0.95
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One (2013) 0.95